Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
The Latest News
Biogen to Participate in the Stifel 2023 CNS Days
Mar 17, 2023
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
Mar 16, 2023
A Statement from Biogen on Access to LEQEMBI™
Mar 13, 2023
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Mar 05, 2023
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Feb 27, 2023